Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

The CDC's Advisory Committee on Immunization Practices recommended the removal of the preservative thimerosal in seasonal influenza vaccines at their meeting.

In parallel, Guyana began weekly reporting of surveillance data to the Pan American Health Organization (PAHO)/World Health Organization (WHO) via FluNet and ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Presented by Alliance for Aging Research {beacon} Health Care Health Care PRESENTED BY The Big Story Vaccine advisers to ...